{"id":"W4385857188","doi":"10.1016/j.eururo.2023.08.004","title":"Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605","year":2023,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; University of British Columbia Hospital","funders":"National Cancer Institute, Cairo University; AstraZeneca; Genentech; American College of Radiology Imaging Network; Astellas Pharma; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Atezolizumab; Bladder cancer; Oncology; Internal medicine; Bacillus (shape); Urology; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001154466,0.001294982,0.001598868,0.0002691764,0.0003135785,0.001064984,0.0006928559,0.001487039,0.005705577],"category_scores_gemma":[0.000835626,0.000490656,0.001802893,0.0002353877,0.0006443433,0.0009244093,0.0003237975,0.003844415,0.001157222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008176566,"about_ca_system_score_gemma":0.001111529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001269537,"about_ca_topic_score_gemma":0.004252166,"domain_scores_codex":[0.9997588,0.00009099972,0.000009309354,0.00004778694,0.00001883999,0.00007429192],"domain_scores_gemma":[0.9996158,0.00006941192,0.00005388769,0.00002856309,0.00002341354,0.000209005],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7230489,0.0366604,0.005117162,0.001558994,0.002874844,0.0004291366,0.0004063445,0.004461964,0.02062176,0.001134736,0.02397452,0.1797113],"study_design_scores_gemma":[0.7685108,0.209501,0.009059622,0.0001066136,0.0005650703,0.000420748,0.0001154659,0.002265626,0.001574756,0.0005307968,0.007309841,0.00003958501],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839469,0.004827322,0.0007477841,0.001701415,0.0008000144,0.001219454,0.001749758,0.000170441,0.004836973],"genre_scores_gemma":[0.9764019,0.00302285,0.001716168,0.003230894,0.0003455276,0.001406429,0.004542621,0.00006706495,0.009266519],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005705577,"threshold_uncertainty_score":0.01908702,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02481132804888801,"score_gpt":0.3123821855103267,"score_spread":0.2875708574614387,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}